Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.56 |
| ▸ | CCKAR | P32238 | 5/20 | 0.41 |
| ▸ | CCKBR | P32239 | 5/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20496415 | 1.00 | GLP1R (0.56) | GLP1RCCKARCCKBRPTGS1PTGS2 | |
| SCHEMBL20496414 | 1.00 | GLP1R (0.56) | GLP1RCCKARCCKBRPTGS1PTGS2 | |
| SCHEMBL3502650 | 1.00 | GLP1R (0.56) | GLP1RCCKARCCKBRPTGS1PTGS2 | |
| SCHEMBL22223308 | 0.95 | GLP1R (0.56) | GLP1RCCKARCCKBRPTGS1PTGS2 | |
| SCHEMBL22223503 | 0.92 | GLP1R (0.52) | GLP1RPTGS1PTGS2FOLH1GLO1 | |
| SCHEMBL3503605 | 0.89 | GLP1R (0.52) | GLP1RCCKARCCKBRFOLH1GLO1 | |
| SCHEMBL22311946 | 0.86 | FOLH1 (0.44) | GLP1RFOLH1 | |
| SCHEMBL19903763 | 0.86 | FOLH1 (0.44) | GLP1RFOLH1 | |
| SCHEMBL22311947 | 0.86 | FOLH1 (0.44) | GLP1RFOLH1 | |
| SCHEMBL22311640 | 0.86 | FOLH1 (0.44) | GLP1RFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2389190-B1 | FGF21 DERIVATIVES WITH ALBUMIN BINDER A-B-C-D-E- AND THEIR USE | NOVO NORDISK AS (DK) | 2018-09-19 | — | — | EP | disclosed |
| US-9480753-B2 | FGF21 derivatives with albumin binder A-B-C-D-E- and their use | NOVO NORDISK A/S (DK) | 2016-11-01 | — | — | US | disclosed |
| US-9255085-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20100216715-A1 | FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use | NOVO NORDISK A/S (DK) | 2010-08-26 | — | — | US | disclosed |
| WO-2010084169-A2 | FGF21 DERIVATIVES WITH ALBUMIN BINDER A-B-C-D-E- AND THEIR USE | NOVO NORDISK A/S (DK) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216715-A1 | FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use | FABP1, FABP4, FGFR1 | GLP1R 45/4885CCKAR 729/4885CCKBR 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.